Cannabis & Hallucinogens: The Psychedelic Renaissance

Introduction

Biological Basis

Genetic predisposition accounts for 40-60% of the vulnerability to addiction, highlighting its nature as a medical condition.

Environmental Influence

Factors like early exposure, trauma, and socioeconomic conditions play critical roles in the development of SUD.

Cannabis is the most widely used illicit drug globally, while hallucinogens are experiencing renewed scientific interest for therapeutic applications. This module explores the endocannabinoid system, the complex pharmacology of cannabis, and the emerging "psychedelic renaissance" in mental health treatment. Understanding these substances is increasingly important as policies evolve and therapeutic applications expand.

Learning Objectives

By the end of this module, you will be able to:

Describe the endocannabinoid system and its functions
Differentiate between THC and CBD effects
Explain Cannabis Use Disorder and its treatment
Identify classic and atypical hallucinogens
Discuss the evidence for psychedelic-assisted therapy

The Endocannabinoid System

Discovery

The endocannabinoid system was discovered in the 1990s while researchers studied how cannabis affects the brain. It is now recognized as a fundamental regulatory system.

Components

Receptors: | Receptor | Location | Function | |----------|----------|----------| | CB1 | Brain, CNS | Psychoactive effects, memory, appetite, pain | | CB2 | Immune system, periphery | Inflammation, immune response |

Endogenous Cannabinoids (Endocannabinoids):

Anandamide (AEA): "Bliss molecule"
2-Arachidonoylglycerol (2-AG): Most abundant endocannabinoid

Enzymes:

FAAH: Breaks down anandamide
MAGL: Breaks down 2-AG

Functions

The endocannabinoid system regulates:

Pain perception
Appetite and metabolism
Mood and stress response
Memory and learning
Sleep
Immune function
Reproduction

Retrograde Signaling

Unlike most neurotransmitters, endocannabinoids work "backwards":

Postsynaptic neuron releases endocannabinoids
They travel backward across synapse
Bind to CB1 on presynaptic neuron
Reduce neurotransmitter release
Fine-tune neural activity

Cannabis Pharmacology

Key Cannabinoids

THC (Delta-9-Tetrahydrocannabinol):

Primary psychoactive component
Partial agonist at CB1 receptors
Produces euphoria, altered perception
Responsible for most intoxication effects

CBD (Cannabidiol):

Non-intoxicating
Complex mechanism (not direct CB1 agonist)
May modulate THC effects
Anti-anxiety, anti-inflammatory properties
FDA-approved for certain seizure disorders (Epidiolex)

Other Cannabinoids:

CBN (Cannabinol): Mildly psychoactive, sedating
CBG (Cannabigerol): Non-intoxicating, under research
THCV: May suppress appetite (opposite of THC)

THC vs. CBD Comparison

| Property | THC | CBD | |----------|-----|-----| | Psychoactive | Yes | No | | CB1 binding | Direct agonist | Indirect/modulatory | | Euphoria | Yes | No | | Anxiety | Can increase | Generally decreases | | Legal status | Restricted | More widely legal | | Drug test | Detected | Not typically detected |

Routes of Administration

| Route | Onset | Duration | Bioavailability | |-------|-------|----------|-----------------| | Smoked | Seconds-minutes | 2-3 hours | 10-35% | | Vaporized | Seconds-minutes | 2-3 hours | Higher than smoking | | Edibles | 30-90 minutes | 4-8 hours | 4-12% | | Sublingual | 15-45 minutes | 2-4 hours | Variable | | Topical | Local effect | Variable | Minimal systemic |

Clinical Pearl: Edibles have delayed onset, leading users to consume more while waiting for effects. This is a common cause of cannabis-related ED visits.

Cannabis Effects and Risks

Acute Effects

Desired:

Euphoria, relaxation
Altered perception (time, sensory)
Increased appetite
Enhanced creativity (subjective)
Social disinhibition

Adverse:

Anxiety, paranoia
Impaired memory and concentration
Impaired motor coordination
Tachycardia
Dry mouth, red eyes

Cannabis Use Disorder

DSM-5 Criteria: Same 11 criteria as other SUDs

Prevalence: ~9% of users develop CUD; higher with early onset

Risk Factors:

Early age of first use
Frequent use
High-potency products
Pre-existing mental health conditions
Family history

Withdrawal Syndrome (onset 1-2 days, peak 2-6 days):

Irritability, anger
Anxiety, restlessness
Decreased appetite
Sleep difficulties
Depressed mood

Long-Term Risks

Cognitive:

Impaired memory and attention (with heavy use)
May persist after cessation
Adolescent use more concerning (developing brain)

Respiratory (smoked):

Chronic bronchitis symptoms
Lung cancer risk unclear (confounded by tobacco)

Psychiatric:

Increased risk of psychosis (especially early use, high THC)
May worsen existing psychiatric conditions
Amotivational syndrome (controversial)

Cannabis Hyperemesis Syndrome:

Cyclic vomiting in chronic heavy users
Compulsive hot bathing for relief
Resolves with cessation
Increasingly recognized

High-Potency Cannabis

Modern cannabis has dramatically higher THC concentrations:

1990s: ~4% THC
Today: 15-25% THC (flower), up to 90% (concentrates)

Concerns:

Greater addiction potential
Increased psychosis risk
More severe withdrawal
Less CBD to offset THC effects

Hallucinogens

Classification

Classic (Serotonergic) Hallucinogens:

LSD (lysergic acid diethylamide)
Psilocybin (magic mushrooms)
DMT (ayahuasca)
Mescaline (peyote)

Dissociatives:

Ketamine
PCP
DXM (dextromethorphan)

Atypical:

MDMA (mixed stimulant/entactogen)
Salvia divinorum

Classic Hallucinogens: Mechanism

Primary action: Agonism at 5-HT2A serotonin receptors

Effects:

Visual hallucinations
Altered perception of time/space
Synesthesia (mixing of senses)
Ego dissolution
Mystical-type experiences
Enhanced emotional processing

Pharmacology of Key Substances

Psilocybin (Magic Mushrooms):

Converted to psilocin (active form)
Duration: 4-6 hours
Low physiological toxicity
No physical dependence

LSD:

Extremely potent (active in micrograms)
Duration: 8-12 hours
No physical dependence
Long-lasting perceptual changes possible (HPPD)

MDMA:

Releases serotonin, dopamine, norepinephrine
Duration: 3-6 hours
Produces euphoria, empathy, emotional openness
Neurotoxicity concerns with heavy use
Hyperthermia risk

The Psychedelic Renaissance

Historical Context

1950s-60s: Early research showed promise for:

Alcoholism treatment
End-of-life anxiety
Depression, anxiety

1970s: Controlled Substances Act ended most research

2000s-Present: Renewed scientific interest with rigorous methodology

Current Research

Psilocybin:

Treatment-resistant depression: FDA "breakthrough therapy" designation
End-of-life anxiety in cancer patients
Alcohol use disorder
Tobacco cessation

MDMA:

PTSD: FDA "breakthrough therapy" designation
Phase 3 trials completed with positive results
Potential FDA approval anticipated

Ketamine:

Esketamine (Spravato) FDA-approved for treatment-resistant depression
Rapid-acting antidepressant
Different mechanism than SSRIs

How Might Psychedelics Work Therapeutically?

Proposed Mechanisms:

Increased neuroplasticity
Disruption of rigid thought patterns
Enhanced emotional processing
Mystical/meaningful experiences
"Resetting" default mode network

Critical Elements:

Set (mindset) and setting (environment)
Therapeutic support before, during, after
Integration of experiences
NOT simply pharmacological effect

Risks and Contraindications

Psychological:

Bad trips (anxiety, panic, paranoia)
Psychotic episodes (rare)
HPPD (Hallucinogen Persisting Perception Disorder)
Destabilization of existing mental illness

Contraindications:

Personal/family history of psychosis
Severe cardiovascular disease (MDMA)
Certain psychiatric medications (serotonin syndrome risk)
Pregnancy

Safety Note: Therapeutic use involves careful screening, controlled settings, and professional support—not recreational use.

Case Study: Therapeutic Potential

Dr. Sharma is asked by a patient with treatment-resistant depression about psilocybin therapy. The patient has tried multiple SSRIs and SNRIs without adequate response and read about clinical trials. She asks, "Should I try magic mushrooms?"

Discussion Questions:

4What would you explain about the current regulatory status of psilocybin?
5How does therapeutic psilocybin use differ from recreational use?
6What screening would be important before considering such treatment?
7What are the risks you would discuss?
8What resources or referrals might be appropriate?

Key Takeaways

The endocannabinoid system regulates pain, mood, appetite, and memory
THC is psychoactive (CB1 agonist); CBD is non-intoxicating with modulatory effects
Cannabis Use Disorder affects ~9% of users; higher with early onset and high-potency products
Cannabis withdrawal is real but not medically dangerous
Classic hallucinogens work primarily through 5-HT2A receptor agonism
Psilocybin and MDMA have FDA breakthrough therapy designations for mental health conditions
Therapeutic psychedelic use requires careful screening, controlled settings, and integration support
Recreational use carries different risk profiles than therapeutic use

Part 2 Complete! Next: Part 3: Behavioral Addictions, beginning with Module 11: Technology, Gambling & Gaming →